Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MnO2R5l1d3SxeHnjxsBie3OjeR?= MUm0PEBp NGDqUnBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OIUuODZizszNMi=> MljCNlE{QDhzOUG=
human colon cancer cell line (LoVo cells) MkLRVJJwdGmoZYLheIlwdiCjc4PhfS=> M{XyUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iY3;sc44h[2GwY3XyJINmdGxibHnu[UApVG:YbzDj[YxteylidYPpcochVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88UU4> MnPDNVE2QTF3MEW=
human LoVo cells NVzGRmlVWHKxbHnm[ZJifGmxbjDhd5NigQ>? MWS0PEB1dyB5MjDo M2nTdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6 NUO4PIdHOjJzOEK5Nlk>
P19 cells MkDtSpVv[3Srb36gZZN{[Xl? MlTTTY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgdoVk\XC2b4KgbY4hWDF7IHPlcIx{NCCLQ{WwQVAvODB{IN88UU4> M1i4WFE2PzdzNEG5
human BJ cells MXnDfZRwfG:6aXRCpIF{e2G7 MnXUO|IhcA>? MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3HsZ4VqdiCDTTDhd5NigSxiSVO1NF0xNjByMjFOwG0v MnLXNlI6OjFyOEG=
human HT-29 cells NWTidGFtTnWwY4Tpc44h[XO|YYm= MVyyJIg> MVvF[oZm[3Rib36gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyb4TlcpRq[WxiaX6gbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiMjDodpMhfXOrbnegTmMuOSC|dHHpcolv\yCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYm= NHmxc5AzOTR{OEO3OS=>
human A549 cells M2HoV2N6fG:2b4jpZ:Kh[XO|YYm= M2\CflczKGh? NX36PYtES3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3S= MUixPFQ5PDd5NR?=
human HT-29 cells MWLGeY5kfGmxbjDhd5NigQ>? MXfJcohq[mm2aX;uJI9nKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIlvKGi3bXHuJGhVNTJ7IHPlcIx{KHW|aX7nJGpEOSCmeXWgd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIIDsZZRmKHKnYXTldkBie3OjeTygTWM2OD1{LkWgcm0> M3fnelIyPTF|Mkmz
human HT-29 cells MkH2SpVv[3Srb36gZZN{[Xl? NXLWZlBvOiCq NHO0WpVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W|c3XkJJJm\HWldHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBi\nSncjCyJIhzeyCkeTD1d4lv\yCMQ{Ggd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHPlcIwu[mG|ZXSgZZN{[XluIFXDOVA:Oi54IH7NMi=> NGjKTXQzOTl5M{GwNS=>
Sf9 cells NWTsbWZwTnWwY4Tpc44h[XO|YYm= Mmq2TY5pcWKrdHnvckBw\iCqdX3hckBUgWtiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{whUUN3ME2zJI5ONg>? M3TBelE5QDJ|N{i0
human HUVEC MWPQdo9tcW[ncnH0bY9vKGG|c3H5 MlvDOFghfG9iN{KgbC=> MoHpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7 MU[yNlE5Ojl{OR?=
P19 cells M3XkR2Z2dmO2aX;uJIF{e2G7 M{fZN2lvcGmkaYTpc44hd2ZiUILveIVqdiCNaX7hd4UhSSCrbjDQNVkh[2WubIOsJGlEPTB;NDDuUU4> MY[xOVc4OTRzOR?=
Sf9 cells NXzFXZlHTnWwY4Tpc44h[XO|YYm= NXTISnM{UW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKG2rbjDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGC= MonFNVc{OTV6NUO=
Sf21 cells MXHGeY5kfGmxbjDhd5NigQ>? NVfZ[ZNwUW6qaXLpeIlwdiCxZjDKRWs{KGW6cILld5Nm\CCrbjDT[lIyKGOnbHzzMEBKSzVyPU[gcm0v MYKxO|A5QDB3OR?=
human colon carcinoma cell line HCT116 M1jNSGZ2dmO2aX;uJIF{e2G7 MoO1R49v[2WwdILheIlwdiC{ZYH1bZJm\CCob4Kg[5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwhdGmwZTDIR3QyOTZuIFnDOVA:PiCwTT6= MV:xOVU{PzN2NR?=
human ST486 cells NVzoOpZ7WHKxbHnm[ZJifGmxbjDhd5NigQ>? NIXtbow1QCC2bzC3NkBp NVznNW5nSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWFQ5PiClZXzsd{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTdibl2u NHnYUm0zOjF6MkmyPS=>
human MDA-MB-231 cells NUfFU|hlS3m2b4TvfIlkyqCjc4PhfS=> M3XET|czKGh? MmD2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCvZYToc4QtKEeLNUC9O{4yKG6PLh?= MV:xPFQ5PDd5NR?=
P19 cells M{OyW2Z2dmO2aX;uJIF{e2G7 NYTEVYlSUW6qaXLpeIlwdiCxZjDDfYNtcW5vZHXw[Y5l\W62IHvpcoF{\SBzIHnuJHAyQSClZXzsd{whUUN3ME24JI5ONg>? M3TkNVE2PzdzNEG5
human DLD1 cells MoiyVJJwdGmoZYLheIlwdiCjc4PhfS=> MWq0PE04OiCq MkPoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? NF7Yd4YzOjF6MkmyPS=>
insect cells NHjwS21HfW6ldHnvckBie3OjeR?= NV3IU4F1UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQbY0yKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMh[nliSGTSSkwhUUN3ME2xNEBvVS5? MnvxNVkyPzlyN{[=
V79 MZ cells M4LETGZ2dmO2aX;uJIF{e2G7 M4HkcGlvcGmkaYTpc44hd2ZiaIXtZY4h[Wymb4P0[ZJwdmVic4nueIhie2ViZYjwdoV{e2WmIHnuJHY4QSCPWjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGuZH;zeIVzd26nIIP5cpRp\XOrczygTWM2OD1zMTDuUU4> NWHGR3RHOjR2MkK1NVk>
P19 cells MXLGeY5kfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> MknuNVU4PzF2MUm=
Sf9 cells MXLGeY5kfGmxbjDhd5NigQ>? MVyyNEBucW6| NYPYZWVkUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAzOCCvaX7zJIJ6KEWOSWPBJIlvKHC{ZYPlcoNmKG:oIEGgeY1wdC:OIFHUVEwhUUN3ME2xOUBvVS5? NUfRcVlLOTd|MUW4OVM>
human PBMC MkjwSpVv[3Srb36gZZN{[Xl? M{XkNlI1KGh? M37CVXN2eHC{ZYPzbY9vKG:oIFnMNkBxem:mdXP0bY9vKGmwIHj1cYFvKFCETVOgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwQVE3KG6PLh?= M{HlVlE5PTh3MES2
human A549 cells NIXrZlREgXSxdH;4bYPDqGG|c3H5 NUnzcpBIPDhiaB?= MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUKwJI5ONg>? MnPLNlU5OjV7M{S=
human CEM cells MVPDfZRwfG:6aXRCpIF{e2G7 NXLHb3JjPzJiaB?= NIjtS4JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v NWT2SmNqOjJ7MkGwPFE>
human HeLa cells NHPONo5EgXSxdH;4bYPDqGG|c3H5 MVG0PEBp M{G0fmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yOUBvVS5? MUGyOVgzPTl|NB?=
human PC3 cells NEi2WmVEgXSxdH;4bYPDqGG|c3H5 MXu0PEBp MljuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUOxJI5ONg>? MYiyOVgzPTl|NB?=
human SF268 cells NF;NT3hEgXSxdH;4bYPDqGG|c3H5 NWnmZoZiPDhiaB?= MlPJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME20OEBvVS5? M1PKfFIyPTF|Mkm0
human MCF7 cells M17TXWN6fG:2b4jpZ:Kh[XO|YYm= NEnEV4c1QCCq M3H3dGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21NEBvVS5? MWSyNVM5QDF7MR?=
HEK293 cells MmnER5l1d3SxeHnjxsBie3OjeR?= MVq3NkBp NELUUG5EgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSnclfsc{Bie3OjeTygTWM2OD13NjDuUU4> MVSyOFc3OzJ4Mh?=
HUE cells M{HmdGZ2dmO2aX;uJIF{e2G7 M{HWOlkxKG2rboO= NHTZbJNKdmirYnn0bY9vKG:oIG\FS2ZTOiCrbjDIWWUh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC2cnXheIVlKG[xcjC5NEBucW6|IHLl[o9z\SCYRVfGJINp[WyuZX7n[UBjgSCHTFnTRUwhUUN3ME23NEBvVS5? NH36SWYzODF5MEG2Ny=>
human A431 cells MXrDfZRwfG:6aXRCpIF{e2G7 NEXRVGMzPCBiaB?= NFHvTmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFI1KGi{czD1d4lv\yCDbn7lfIlvKF[nRlnUR{9xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJ6KE2WVDDhd5NigSxiSVO1NF04OCCwTT6= MlHDNlI2PDFyNUG=
human Jurkat cells M2XWN3Bzd2yrZnXyZZRqd25iYYPzZZk> NIfqSolCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGpCUzNiZYjwdoV{e2mwZzDJUFIue3SrbYXsZZRm\CCqdX3hckBLfXKtYYSgZ4VtdHNuIFnDOVA:PzFibl2u MVWxPVQzPzJyMx?=
HEK293 cells NXvF[JFpTnWwY4Tpc44h[XO|YYm= NWS0Z5h2UW6qaXLpeIlwdiCxZjDJUE05KHKnbHXhd4Uh[nliSFXLNlk{KGOnbHzzJIV5eHKnc4PpcochWEuFLXLleIEzNCCLQ{WwQVc4KG6PLh?= NIXrVmEyPTd5MUSxPS=>
human KE-97 cells MnrQR5l1d3SxeHnjxsBie3OjeR?= NUDLeGliPzJiaB?= MmrBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2UuQTdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOyEQvF2u NICzOJEzPDN{OEK4Ny=>
human CHOK1 cells MlfFR5l1d3SxeHnjxsBie3OjeR?= MX:0PEBp NGL5UHZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEUE:NMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5zMzFOwG0v MWmyNVUyOzJ7NB?=
mouse NIH/3T3 cells NVPIRXJrS3m2b4TvfIlkyqCjc4PhfS=> MX:5OkBp NIDycYxEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBPUUhxM2SzJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5{IN88UU4> MYGyOFM3OTV{MR?=
human A2780 cells MoPGR5l1d3SxeHnjxsBie3OjeR?= NEPR[IE6PiCq NUXMWYhwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> NF;iVYQzPDN4MUWyNS=>
human 8505C cells MX;DfZRwfG:6aXRCpIF{e2G7 NGHnb5Y6PiCq MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjC4OVA2SyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNkDPxE1w NWLHcZFqOjR|NkG1NlE>
human 518A2 cells M4\IV2N6fG:2b4jpZ:Kh[XO|YYm= MoPYPVYhcA>? Ml7CR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gOVE5STJiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOiEQvF2u NEjiOmUzPDN4MUWyNS=>
human HuH7 cells Ml33R5l1d3SxeHnjxsBie3OjeR?= MWS3NkBp NF\UfJhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjNizszNMi=> Mn7KNlQ{Ojh{OEO=
FL5.12-Akt1 cells MljSVJJwdGmoZYLheIlwdiCjc4PhfS=> M3LNZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmw2NjF{LVHreFEh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOjlizszNMi=> NH73PXEyPjRyM{[yOi=>
human MiaPaCa-2 cells Ml\tVJJwdGmoZYLheIlwdiCjc4PhfS=> MlS5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPaXHQZWNiNTJiY3XscJMtKEmFNUC9NE4{PyEQvF2u NUnVXFBvOTZ2MUO3PFA>
human BGC823 cells NXjYS3BlS3m2b4TvfIlkyqCjc4PhfS=> Mm\jO|IhcA>? M4D5bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6IN88UU4> NHzJTGszPDN{OEK4Ny=>
human MCF7 cells Mk[0R5l1d3SxeHnjxsBie3OjeR?= M{\nOFk3KGh? MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD60JO69VS5? MWGyOFM3OTV{MR?=
human A549 cells M2PpR2N6fG:2b4jpZ:Kh[XO|YYm= MmXtPVYhcA>? NUf5UIROS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u Mn7ZNlQ{PjF3MkG=
HEK293 cells M{jBR2N6fG:2b4jpZ:Kh[XO|YYm= M{HhUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczygSWM2OD1{IN88UU4> NUjaN2pNOjV|MU[zNVc>
human Raji cells  M1vLW2N6fG:2b4jpZ:Kh[XO|YYm= NXrpUHlSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6= M4D5WlI2OzF4M{G3
human HepG2 cells NWfieo1DS3m2b4TvfIlkyqCjc4PhfS=> NVL0VpE2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVA:OiEQvF2u M1vvc|I2OzF4M{G3
human BJ cells M4ezUWN6fG:2b4jpZ:Kh[XO|YYm= M{TKcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzMEBGSzVyPUKg{txONg>? NEjxVVAzPTNzNkOxOy=>
human U937 cells NXjnSnplS3m2b4TvfIlkyqCjc4PhfS=> M3vCSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w M3T4RVE4ODh6ME[3

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID